论文信息 - Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy

Objective: This is one of two separate clinical trials to evaluate the efficacy and safety of modafinil, a novel wake-promoting agent, in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Methods: In this 9-week, randomized, placebo-controlled, double-blind, 21-center clinical trial, patients were randomized to receive fixed daily doses of modafinil 200 mg, modafinil 400 mg, or placebo. A placebo-controlled, 2-week treatment discontinuation phase was included to evaluate the effects of withdrawal on patients who had been receiving modafinil. A total of 271 patients who were naïve to modafinil received study medication in the 9-week trial and 240 patients received study medication in the discontinuation phase. Results: Treatment with modafinil resulted in significant improvement in two objective measures of EDS: the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Additionally, patient self-assessment of sleepiness was significantly improved, as measured by the Epworth Sleepiness Scale, and level of illness was significantly reduced on the independent clinician assessment, the Clinical Global Impression of Change. Nighttime sleep, monitored by nocturnal polysomnography, was not adversely effected with modafinil treatment compared with placebo treatment. The most frequent adverse experience was headache, which was not significantly greater for modafinil than placebo. During treatment discontinuation, individuals who had been receiving modafinil experienced a return of their EDS to baseline levels. During treatment discontinuation, patients did not experience symptoms associated with amphetamine withdrawal syndrome. For up to 9 weeks of daily use there was no evidence for the development of dependence at the dose levels studied. Conclusion: The data indicate that modafinil has an excellent safety profile and is very well tolerated. Modafinil is an effective treatment for excessive daytime sleepiness in narcolepsy and shows continued efficacy with up to 9 weeks of daily use.

[1] T. Sakurai,et al. Structure and Function of Human Prepro-orexin Gene* , 1999, The Journal of Biological Chemistry.

[2] D. Fry,et al. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy , 1998, Annals of neurology.

[3] R. Daroff,et al. The International Classification of Sleep Disorders , 1991, Neurology.

[4] G. Koob,et al. Narcolepsy and its treatment with stimulants. ASDA standards of practice. , 1994, Sleep.

[5] J. Siegel,et al. Narcolepsy A Key Role for Hypocretins (Orexins) , 1999, Cell.

[6] M. Jouvet,et al. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7] W. Ganado. The narcolepsy syndrome. , 1958, Neurology.

[8] Emmanuel Mignot,et al. The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[9] M. Jouvet,et al. ネコ脳のアンフェタミン,メチルフェニデート,モダフィニルの覚醒作用における標的ニューロンのc‐fos免疫組織化学による検索 , 1996 .

[10] N. Dahmen,et al. Increased frequency of migraine in narcoleptic patients , 1999, Neurology.

[11] M. Mitler,et al. Sleep studies on canine narcolepsy: pattern and cycle comparisons between affected and normal dogs. , 1977, Electroencephalography and clinical neurophysiology.

[12] M M Mitler,et al. Treatment of narcolepsy with methamphetamine. , 1993, Sleep.

[13] D. Jasinski. An evaluation of the abuse potential of modafinil using methylphenidate as a reference , 2000, Journal of psychopharmacology.

[14] E. Wolpert. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. , 1969 .

[15] C. Guilleminault,et al. Modafinil binds to the dopamine uptake carrier site with low affinity. , 1994, Sleep.

[16] P. Underhill,et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. , 1994, Sleep.

[17] H. Moldofsky,et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy , 1997, Neurology.

[18] W. Feuerlein,et al. [Drug addiction and drug abuse]. , 1969, Munchener medizinische Wochenschrift.

[19] J. Costentin,et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice , 1995, European Neuropsychopharmacology.

[20] C. Guilleminault,et al. FAMILIAL PATTERNS OF NARCOLEPSY , 1989, The Lancet.

[21] Jon T. Willie,et al. Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[22] M. Carskadon,et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. , 1986, Sleep.

[23] E. Corruble,et al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo , 1993, European Psychiatry.

[24] P. Contreras,et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil , 1998, Neuroscience Letters.

[25] A. Pol. Hypothalamic Hypocretin (Orexin): Robust Innervation of the Spinal Cord , 1999 .

[26] M M Mitler,et al. A normative study of the maintenance of wakefulness test (MWT). , 1997, Electroencephalography and clinical neurophysiology.

[27] R. Stafford,et al. Principles and Practice of Sleep Medicine , 2001 .

[28] M. Jouvet,et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat , 1992, Brain Research.

[29] E. Mignot,et al. Neuropharmacology and neurochemistry of canine narcolepsy. , 1994, Sleep.

[30] William H. Beers,et al. The Scripps Research Institute , 1996, Current Biology.

[31] M. Johns,et al. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[32] M. Mitler,et al. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. , 1982, Electroencephalography and clinical neurophysiology.